Cargando…

Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada

BACKGROUND: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy profile to other atypical antipsychotics. In addition, it is associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lachaine, Jean, Beauchemin, Catherine, Mathurin, Karine, Gilbert, Dominique, Beillat, Maud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905654/ https://www.ncbi.nlm.nih.gov/pubmed/24450548 http://dx.doi.org/10.1186/1471-244X-14-16

Ejemplares similares

Asenapine for bipolar disorder
por: Scheidemantel, Thomas, et al.
Publicado: (2015)

Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
por: Lachaine, Jean, et al.
Publicado: (2016)

A Review of Asenapine in the Treatment of Bipolar Disorder
por: Vieta, Eduard, et al.
Publicado: (2017)

Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context
por: Caresano, Chiara, et al.
Publicado: (2014)

Asenapine augmentation in bipolar disorders: a case series
por: Marazziti, Donatella, et al.
Publicado: (2016)

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
por: Bishara, Delia, et al.
Publicado: (2009)

Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder
por: Gonzalez, Jodi M, et al.
Publicado: (2011)

The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder
por: Pompili, Maurizio, et al.
Publicado: (2011)

New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania
por: Warren, Calvert G, et al.
Publicado: (2013)

Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review
por: Stepanova, Ekaterina, et al.
Publicado: (2017)

Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder
por: Citrome, Leslie, et al.
Publicado: (2017)

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review
por: Hillhouse, Erin, et al.
Publicado: (2021)

Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study
por: Aguglia, Andrea, et al.
Publicado: (2018)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
por: Harasymowycz, Paul, et al.
Publicado: (2022)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome, Leslie
Publicado: (2011)

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis
por: Guinan, Kimberly, et al.
Publicado: (2022)

Treating Borderline personality disorder with Asenapine : Case report
por: Aboelenien, S. K. I. M., et al.
Publicado: (2023)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis
por: Cazorla, Pilar, et al.
Publicado: (2013)

The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA
por: Ágh, Tamás, et al.
Publicado: (2016)

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada
por: Lachaine, Jean, et al.
Publicado: (2023)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight
por: Findling, Robert L, et al.
Publicado: (2018)

Use, tolerability and compliance of spironolactone in the treatment of heart failure
por: Lachaine, Jean, et al.
Publicado: (2011)

The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis
por: Thomas, Jennifer E., et al.
Publicado: (2015)

Asenapine effects in animal models of psychosis and cognitive function
por: Marston, Hugh M., et al.
Publicado: (2009)

Supersensitivity Psychosis and Its Response to Asenapine in a Patient with Delusional Disorder
por: Rajkumar, Ravi Philip
Publicado: (2014)

The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France
por: Touchon, Jacques, et al.
Publicado: (2013)

Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada
por: Lachaine, Jean, et al.
Publicado: (2021)

Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial
por: Findling, Robert L., et al.
Publicado: (2016)

Asenapine, a new sublingual atypical antipsychotic
por: Balaraman, R, et al.
Publicado: (2010)

Asenapine pharmacokinetics and tolerability in a pediatric population
por: Dogterom, Peter, et al.
Publicado: (2018)

Transdermal Asenapine in Schizophrenia: A Systematic Review
por: Carrithers, Brennan, et al.
Publicado: (2020)

Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada
por: Lachaine, Jean, et al.
Publicado: (2019)

Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine
por: Takao, Nagara, et al.
Publicado: (2021)

Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database
por: Lachaine, Jean, et al.
Publicado: (2013)

Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070)
por: Suzuki, Katsumi, et al.
Publicado: (2021)

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials
por: Szegedi, Armin, et al.
Publicado: (2011)

Asenapine-induced double incontinence: A rare case report
por: Singh, Gurvinder Pal, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lbg0rgscopetrpovs3aaaof9ka